|
Barry, B.W., 2002. Drug delivery routes in skin: a novel approach. Adv. Drug Deliv. Rev. 54, Suppl. 1, S31-S40. Bjerregaard, S., Wulf-Andersen, L., Stephens, R.W., Lund, L.R., Vermehren, C., Söderberg, I., Frokjaer, S., 2001. Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J. Control. Release 71, 87-98. Boonme, P., 2007. Applications of microemulsions in cosmetics. J. Cosmet. Dermatol. 6, 223-228.
Boothby, L.A., Doering, P.L., 2007. Buprenorphine for the treatment of opioid dependence. Am. J. Health-Syst. Pharm. 64, 266-272. Bose, S., Ravis, W.R., Lin, Y.J., Zhang, L., Hofmann, G.A., Banga, A.K., 2001. Electrically-assisted transdermal delivery of buprenorphine. J. Control. Release 73, 197-203. Boyum, A., Lovhaug, D., Tresland, L., Nordlie, E.M., 1991. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34, 697-712. Brown, M.B., Traynor, M.J., Martin, G.P., Akomeah, F.K., 2008. Transdermal drug delivery systems: skin perturbation devices. Methods Mol. Biol. 437, 119-139. Bunjes, H., Koch, M.H., Westesen, K., 2003. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci. 92, 1059-1520. Bunjes, H., Westesen, K., Koch, M.H.J., 1996. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129, 159-173. Buszello, K., Harnish, S., Müller, R.H., Müller, B.W., 2000. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solutol HS 15. Eur. J. Pharm. Biopharm. 49, 143-149. Cady, J., 2001. Understanding opioids tolerance in cancer pain. Oncol. Nurs. Forum. 28, 1561-1568. Chan, S.Y., Li, W.P.A., 1989. Prodrugs for dermal delivery. Int. J. Pharm. 55, 1-16. Charcosset, C., El-Harati, A., Fessi, H., 2005. Preparation of solid lipid nanoparticles using a membrane contactor. J. Control. Release 108, 112-120. Chen, H., Chang, X., Du, D., Liu, W., Liu, J., Weng, T., Yang, Y., Xu, H., Yang, X., 2006. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release 110, 296-306. Chen, Y., Dalwadi, G., Benson, H.A.E., 2004. Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 1, 361-376. Chin, L.S., Huang, K.L., Liu, K.S., Chu, C.C., Tzeng, J.I., Ho, S.T., Wang, J.J., 2005. An esterification method for synthesizing prodrugs of buprenorphine. Acta Anaesthe. Taiwan. 43, 223-229. Clogston, J., Rathman, J., Tomasko, D., Walker, H., Caffrey, M., 2000. Phase behavior of a monoacylglycerol (Myverol 18-99K)/water system. Chem. Phys. Lipids 107, 191-220. Cury-Boaventura, M.F., Gorjão, R., de Lima, T.M., Piva, T.M., Peres, C.M., Soriano, F.G., Curi, R., 2006. Toxicity of a soybean oil emulsion on human lymphocytes and neutrophils. J. Parenter. Enteral. Nutr. 30, 115-123. Dahan, A., Yassen, A., Bijl, H., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., Danhof, M., 2005. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 94, 825-34. Doh, H.J., Cho, W.J., Yong, C.S., Choi, H.G., Kim, J.S., Lee, C.H., Kim, D.D., 2003. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J. Pharm. Sci. 92, 1008-1017. Driscoll, D.F., 2006. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm. Res. 23, 1959-1969. DuPen, A., Shen, D., Ersek, M., 2007. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manage. Nurs. 8, 113-121. Esposito, E., Fantin, M., Marti, M., Drechsler, M., Paccamiccio, L., Mariani, P., Sivieri, E., Lain, F., Menegatti, E., Morari, M., Cortesi, R., 2008. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 25, 1521-1530. Ettmayer, P., Amidon, G.L., Clement, B., Testa, B., 2004. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47, 2393-2404. Fang, J.Y., Leu, Y.L., 2006. Prodrug strategy for enhancing drug delivery via skin. Curr. Drug Discov. Technol. 3, 211-224. Gokce, E.H., Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Güneri, T., Caramella, C., 2008. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 364, 76-86. Gopal, S., Tzeng, T.B., Cowan, A., 2002. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur. J. Pharm. Sci. 15, 287-293. Gutiérrez, J.M., Gonzalez, C., Maestro, A., Pey, C.M., Nolla, J., 2008. Nano-emulsions: new applications and optimization of their preparation. Curr. Opin. Colloid Interface Sci. 13, 245-251. Hammell, D.C., Stolarczyk, E.I., Klausner, M., Hamad, M.O., Crooks, P.A., Stinchcomb, A.L., 2005. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J. Pharm. Sci. 94, 828-836. Han, J., Davis, S.S., Washington, C., 2001. Physical properties and stability of two emulsion formulations of propofol. Inter. J. Pharm. 215, 207-220. Hu, F.Q., Jiang, S.P., Du, Y.Z., Yuan, H., Ye, Y.Q., Zeng, Q.S., 2006. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm. 314, 83-89. Hwang, T.L., Li, G.L., Lan, Y.H., Chia, Y.C., Hsieh, P.W., Wu, Y.H., Wu, Y.C., 2009. Potent inhibition of superoxide anion production in activated human neutrophils by isopedicin, a bioactive component of the Chinese medicinal herb Fissistigma oldhamii. Free Rad. Bio. Med. 46, 520-528. Imoto, H., Zhou, Z., Stinchcomb, A.L., Flynn, G., 1996. Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol. Pharm. Bull. 19, 263-267. Jenning, V., Thünemann, A.F., Gohla, S.H., 2000. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199, 167-177. Johson, R.E., Fudala, P.J., Payne, R., 2005. Buprenorphine: considerations for pain management. J. Pain Symptom Manage. 29, 297-326. Jores, K., Haberland, A., Wartewig, S., Mäder, K., Mehnert, W., 2005. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm. Res. 22, 1887-1897. Jores, K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C., Mäder, K., 2004. Investigation on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release 95, 217-227. Jores, K., Mehnert, W., Mäder, K., 2003. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. 20, 1274-1283. Juntunen, J., Majumdar, S., Sloan, K.B., 2008. The effect of water solubility of solutes on their flux through human skin in vitro: a prodrug database integrated into the extended Flynn database. Int. J. Pharm. 351, 92-103. Kalia, Y.N., Guy, R.H., 2001. Modeling transdermal drug release. Adv. Drug Deliv. Rev. 48, 159-172. Katzung, B.G., 2004. Basic & chinical pharmacology 9th edition, the McGraw-Hill Companies 497-516. Kaur, I.P., Bhandari, R., Bhandari, S., Kakkar, V., 2008. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97-109. Kim, B.D., Choi, H.K., 2005. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur. J. Pharm. Sci. 24, 199-205. Kogan, A., Garti, N., 2006. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 123-126, 369-385. Kuo, Y.C., Chen, H.H., 2009. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365, 206-213. Kuo, Y.C., Chen, H.H., 2009. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365, 206-213. Lipp, R., Laurent, H., Günther, C., Riedl, J., Esperling, P., Täuber, U., 1998. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm. Res. 15, 1419-1424. Liu, A.C., Lin, T.Y., Su, L.W., Fuh, M.R., 2008. Online solid-phase extraction liquid chromatography-electrospray-tandem mass spectrometry analysis of buprenorphine and three metabolites in human urine. Talanta 75, 198-204. Liu, K.S., Lin, C.N., Shieh, J.P., Chu, C.C., Kuei, C.H., Wang, J.J., 2006. The novel depot of buprenorphine propionate has a long-acting effect on physical dependence on morphine. Drug Develop. Res. 67, 462-469. Liu, S.Y., Liu, K.S., Kuei, C.H., Tzeng, J.I., Ho, S.T., Wang, J.J., 2005. Simultaneous determination of buprenorphine and its prodrug, buprenorphine propionate, by high-preformance liquid chromatography with fluorescence detection: application to pharmacokinetic studies in rabbits. J. Chromatogr. B 818, 233-239. Lombardi Borgia, S., Regehly, M., Sivaramakrishnan, R., Mehnert, W., Korting, H.C., Danker, K., Röder, B., Kramer, K.D., Schäfer-Korting, M., 2005. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 110, 151-163. Mehnert, W., Mäder, K., 2001. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165-196. Meidan, V.M., Bonner, M.C., Michniak, B.B., 2005. Transfollicular drug delivery-is it a reality? Int. J. Pharm. 306, 1-14. Moghimi, H.R., Williams, A.C., Barry, B.W., 1996. A lamellar matrix model for stratum corneum intercellular lipids. Ⅱ. Effect of geometry of the stratum corneum on permeation of model drugs 5-fluorouracil and oestradiol. Inter. J. Pharm. 131, 117-129. Montenegro, L., Carbone, C., Maniscalco, C., Lambusta, D., Nicolosi, G., Ventura, C.A., Puglisi, G., 2007. In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. Int. J. Pharm. 336, 257-262. Müller, R.H., Mäder, K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177. Müller, R.H., Petersen, R.D., Hommoss, A., Pardeike, J., 2007. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 59, 522-530. Müller, R.H., Radtke, M., Wissing, S.A., 2002a. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242, 121-128. Müller, R.H., Radtke, M., Wissing, S.A., 2002b. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54, Suppl. 1, S131-S155. Muguet, V., Seiller, M., Barratt, G., Ozer, O., Marty, J.P., Grossiord, J.L., 2001. Formulation of shear rate sensitive multiple emulsions. J. Control. Release 70, 37-49. Nathan, C., 2006. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6, 173-182. Ohtani, M., 2007. Basic pharmacology of buprenorphine. Eur. J. Pain Supp. 1, 69-73. Ostacolo, C., Marra, F., Laneri, S., Sacchi, A., Nicoli, S., Padula, C., Santi, P., 2004. Α-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. J. Control. Release 99, 403-413. Park, I., Kim, D., Song, J., In, C.H., Jeong, S.W., Lee, S.H., Min, B., Lee, D., Kim, S.O., 2008. Buprederm™, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm. Res. 25, 1052-1062. Pavan, B., Dalpiaz, A., Ciliberti, N., Biondi, C., Manfredini, S., Vertuani, S., 2008. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13, 1035-1065. Pople, P.V., Singh, K.K., 2006. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm. Sci. Tech. 7, Article 91. Puglia, C., Blasi, P., Rizza, L., Schoubben, A., Bonina, F., Rossi, C., Ricci, M., 2008. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm. 357, 295-304. Que, J., Lin, L.C., Chu, C.C., Liu, K.S., Ho, S.T., Wang, J.J., 2005. A novel long-acting analgesic: buprenorphine palmitate in rats. Acta Anaesthe. Taiwan. 43, 11-16. Radtke, M., Souto, E.B., Müller, R.H., 2005. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm. Tech. Europe 17, 45-50. Raffa, R.B., Ding, Z., 2007. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 9, 145-152. Ranade, V.V., 1991. Drug delivery systems. 6. Transdermal drug delivery. J. Clin. Pharmacol. 31, 401-418. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., Savolainen, J., 2008. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255-270. Rautio, J., Taipale, H., Gynther, J., Nevalainen, T., Jarvinen, T., 1998. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J. Pharm. Sci. 87, 1622-1628. Roy, S.D., Roos, E., Sharma, K., 1994. Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci. 83, 126-130. Russo, M.A., Wasiak, J., 2007. A clinical snapshot of transdermal buprenorphine in pain management. Eur. J. Pain Suppl. 1, 74-77. Sarker, D.K., 2005. Engineering of nanoemulsions for drug delivery. Curr. Drug Deliv. 2, 297-310. Schäfer-Korting, M., Mehnert, W., Korting, H.C., 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 59, 427-443. Schubert, M.A., Harms, M., Müller-Goymann, C.C., 2006. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur. J. Pharm. Sci. 27, 226-236. Shah, K.A., Date, A.A., Joshi, M.D., Patravale, V.B., 2007. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Inter. J. Pharm. 345, 163-171. Singh, S., Singh, J., 1993. Trandermal drug delivery by passive diffusion and iontophoresis: a review. Med. Res. Rev. 13, 569-621. Singla, A.K., Garg, A., Aggarwal, D., 2002. Paclitaxel and its formulations. Int. J. Pharm. 235, 179-192. Sittl, R., Griessinger, N., Likar, R., 2003. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicentre, randomized, double-blind, placebo-controlled trial. Clin. Ther. 25, 150-168. Sloan, K.B., Wasdo, S., 2003. Designing for topical delivery: prodrugs can make the difference. Med. Res. Rev. 23, 763-793. Sorge, J., Sittl, R., 2004. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 26, 1808-1820. Souto, E.B., Almeida, A.J., Müller, R.H., 2007. Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery: structure, protection and skin effects. J. Biomed. Nanotechnol. 3, 317-331. Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H., 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278, 71-77. Stinchcomb, A.L., Dua, R., Paliwal, A., Woodard, R.W., Flynn, G.L., 1995. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 12, 1526-1529. Stinchcomb, A.L., Paliwal, A., Dua, R., Imoto, H., Woodard, R.W., Flynn, G.L., 1996. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm. Res. 13, 1519-1523. Swenson, J., Olgun, S., Radjavi, A., Kaur, T., Reilly, C.M., 2007. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Eur. J. Pharmacol. 567, 67-76. Teeranachaideekul, V., Boonme, P., Souto, E.B., Müller, R.H., Junyaprasert, B.V., 2008. Influence of oil content on physicochemical properties and skin distribution of nile red-loaded NLC. J. Control. Release 128, 134-141. Teeranachaideekul, V., Souto, E.B., Junyaprasert, V.B., Müller, R.H., 2007. Cetyl palmitate-based NLC for topical delivery of coenzyme Q10-development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 67, 141-148. Thomas, J.D., Sloan, K.B., 2008. In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrug of phenols for topical delivery: ACOM prodrugs of acetaminophen. Int. J. Pharm. 346, 80-88. Trotta, M., Peira, E., Carlotti, M.E., Gallarate, M., 2004. Deformable liposomes for dermal sdministration of methotrexate. Int. J. Pharm. 270, 119-125. Vaddi, H.K., Hamad, M.O., Chen, J., Banks, S.L., Crooks, P.A., Stinchcomb, A.L., 2005. Human skin permeation of branched-chain 3-O-alkyl ester and carbonate prodrugs of naltrexone. Pharm. Res. 22, 758-765. Valjakka-Koskela, R., Kirjavainen, M., Monkkonen, J., Urtti, A., Kiesvaara, J., 1998. Enhancement of percutaneous absorption of naproxen by phospholipids. Int. J. Pharm. 175, 225-230. Vance, D.E., Vance, J. (eds) 2002. Biochemistry of lipids, lipoproteins and membranes. (4th edition). Elsevier Publisher, Amsterdam. Venkateswarlu, V., Manjunath, K., 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95, 627-638. Vighi, E., Ruozi, B., Montanari, M., Battini, R., Leo, E., 2007. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur. J. Pharm. Biopharm. 67, 320-328. Vivek, K., Reddy, H., Murthy, R.S.R., 2007. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of danzapine-loaded solid lipid nanoparticles. AAPS Pharm. Sci. Tech. 8, Article 83. Wang, J.J., Ho, S.T., Hu, O.Y.P., Chu, K.M., 1995. An innovative cold tail-flick test: the cold ethanol tail-flick test. Anesth. Analg. 80, 102-107. Wilding, I.R., Davis, S.S., Rimoy, G.H., Rubin, P., Kurihara-Bergstrom, T., Tipnis, V., Berner, B., Nightingale, J., 1996. Pharmacokinetic evaluation of transdermal buprenorphine in man. Inter. J. Pharm. 132, 81-87. Wissing, S., Craig, D.Q.M., Barker, S.A., Moore, W.D., 2000. An investigation into the use of stepwise isothermal high sensitivity DSC as a means of detecting drug-excipient incompatibility. Inter. J. Pharm. 199, 141-150. Wissing, S.A., Kayser, O., Müller, R.H., 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257-1272. Yang, C., Lan, K.M., Liu, K.S., Chen, Y.W., Tzeng, J.I., Ho, S.T., Wang, J.J., 2004. The antinociceptive effect of buprenorphine and long-acting ester buprenorphine benzoate in rat. Acta Anaesthe. Taiwan. 42, 135-139. Zhang, X., Pan, W., Gan, L., Zhu, C., Gan, Y., Nie, S., 2008. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. 56, 1645-1650. zur Mühlen, A., Schwarz, C., Mehnert, W., 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149-155.
|